HOME >> MEDICINE >> NEWS
Have researchers found a biomarker to signal a more agressive form of prostate cancer?

DENVER--Researchers say they have identified a biomarker that indicates a more agressive form of prostate cancer. Fox Chase Cancer Center's chairman of radiation oncology, Alan Pollack, M.D., Ph.D., presented the findings today at the 47th Annual Meeting of the American Society for Therapeutic Radiology and Oncology in Denver, Colo.

"Staging factors for prostate cancer such as PSA and the Gleason score are extremely useful in predicting prostate cancer outcome," explained Pollack. "However, new biomarkers hold promise in strengthening our ability to predict response to treatment. By identifying the more virulent forms of prostate cancer, we may be able to tailor treatment or develop therapies to target the abnormalities identified."

In the Radiation Therapy Oncology Group-sponsored study (RTOG 92-02), Pollack and his colleagues show that the overexpression of a protein called MDM2 is a strong and independent predictor that the prostate cancer will metastasize beyond the prostate gland and indicates an increased chance of death from the disease.

The study involved 469 men treated with radiation and short- and long-term androgen deprivation therapy. The median follow-up was 70.5 months. An immunohistochemical analysis was conducted on prostate tissue to determine the amount of MDM2 in the prostate cancer cells.

While other biomarkers were associated with biochemical failure, distant metastasis or overall mortality, MDM2 was consistently associated with all three outcomes. MDM2 was associated with a doubling of distant metastasis (10 to 20 percent) and a nearly 10 percent reduction in five-year survival.


'"/>

Contact: Karen C. Mallet
karen.mallet@fccc.edu
215-728-2700
Fox Chase Cancer Center
17-Oct-2005


Page: 1

Related medicine news :

1. Stanford researchers find culprit in aging muscles that heal poorly
2. UCLA researchers awarded $9M contract for study identifiying antibiotic treatment for MRSA
3. Penn researchers discover novel pathway for increasing good cholesterol
4. Theory of facial aging gets a facelift from UT Southwestern researchers
5. UIC researchers to develop new drugs to fight bioterrorism
6. UQ researchers discover some of the oldest forms of life
7. U of M researchers discover new method to combat HIV
8. U of M researchers assess effectiveness of computerized physician order entry system
9. Nepalese researchers identify cost-effective treatment for drug-resistant typhoid
10. Physician-researchers often less successful in obtaining NIH funding
11. UCLA researchers develop new nanomaterials to deliver anti-cancer drugs to cells

Post Your Comments:
(Date:8/31/2015)... ... August 31, 2015 , ... For 12 years, since 2004, the ... 26th as Mesothelioma Awareness Day . On this day, and in the weeks ... of becoming involved and helping the cause. , “One of the ways a person ...
(Date:8/31/2015)... ... August 31, 2015 , ... Chicago-based company The Mood ... to raise money and awareness for breast and ovarian health. During September ... incandescent Mood-lite sold to Bright Pink® to encourage households, dorms, and offices around ...
(Date:8/31/2015)... ... 31, 2015 , ... The Brooks Group, a global sales ... department devoted to helping organizations identify and keep the best talent both inside ... Brooks Group believes in offering a solution that goes beyond simply providing assessments ...
(Date:8/31/2015)... ... August 31, 2015 , ... ERT, a leading global provider ... solutions will demonstrate multiple prototypes from its Innovation Lab during its 8th Annual ... the only European event dedicated to providing case studies and pragmatic information on ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... certifies products for the water, food, health sciences and consumer goods industries, has ... for their advanced iron filtration media, Pro-OX Manganese Dioxide. , Developed by a ...
Breaking Medicine News(10 mins):Health News:Cancer Research Organization Paints the World in Mesothelioma Awareness 2Health News:Cancer Research Organization Paints the World in Mesothelioma Awareness 3Health News:Mood-lites® is proud to launch “Brighten Our World" Campaign to Raise Money and Awareness for Breast and Ovarian Health Across America in Partnership with Bright Pink® 2Health News:Mood-lites® is proud to launch “Brighten Our World" Campaign to Raise Money and Awareness for Breast and Ovarian Health Across America in Partnership with Bright Pink® 3Health News:The Brooks Group Introduces Talent Management Division 2Health News:The Brooks Group Introduces Talent Management Division 3Health News:ERT to Demonstrate Innovation Lab Prototypes at European PRO / eCOA Congress 2Health News:ERT to Demonstrate Innovation Lab Prototypes at European PRO / eCOA Congress 3Health News:NSF International Has Recognized Clean Water Systems & Stores Inc Facility 2Health News:NSF International Has Recognized Clean Water Systems & Stores Inc Facility 3
(Date:8/31/2015)... PRINCETON, N.J. , Aug. 31, 2015  /PRNewswire/ ... Company), a late-stage biopharmaceutical company developing products that ... inflammation, oncology and biodefense, announced today it has ... by the Data Review Committee (DRC) earlier this ... SGX942.  SGX942 is a first-in-class innate defense regulator ...
(Date:8/31/2015)... , Aug. 31, 2015  Asterias Biotherapeutics, ... on the emerging field of regenerative medicine, today ... at Chicago -based Rush University ... evaluating activity of escalating doses of AST-OPC1 (oligodendrocyte ... and motor complete cervical spinal cord injury (SCI). ...
(Date:8/31/2015)... and STAMFORD, Conn. , Aug. ... of Eisai Co., Ltd., and Purdue Pharma L.P. announced ... agreement for the development and commercialization of Eisai,s clinical ... antagonist entering Phase III clinical development for the treatment ... the agreement, Eisai and Purdue Pharma will share the ...
Breaking Medicine Technology:Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 2Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 3Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 4Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 5Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 6Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 2Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 3Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 4Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 5
Cached News: